Second, if NF-κB is in fact elevated in ccRCC tumors – and not just in RCC cell lines - then targeting NF-κB provides an exciting new therapeutic option for advanced ccRCC. This evidence concerns the gene NFKB1 and nonpapillary renal cell carcinoma.